A runny nose and mild cough rarely trigger alarm. That is exactly what makes respiratory syncytial virus tricky. RSV usually looks like an ordinary cold, and for most healthy people, that is exactly what it turns out to be. But in infants, older adults, and people with certain chronic conditions, the same virus can progress to serious breathing difficulty requiring hospitalization.
Common RSV symptoms include a runny nose, congestion, reduced appetite, coughing, sneezing, fever, and wheezing, while very young infants may show irritability, reduced activity, or noticeable breathing difficulty instead of the more typical cold symptoms. Recognizing that difference matters, particularly for parents of newborns and caregivers of older adults.
RSV Symptoms: What It Usually Looks Like
Most RSV infections in healthy children and adults produce cold-like symptoms that resolve within one to two weeks without specific treatment. Symptoms typically appear four to six days after exposure and often begin with mild congestion and low-grade fever before progressing to cough.
Infants can present differently than older children and adults, sometimes showing irritability, decreased activity, or breathing problems rather than the classic runny nose and cough pattern. Children generally show the same core symptom set as adults, though wheezing and breathing difficulty tend to be more pronounced given their smaller airways.
Adults, particularly otherwise healthy adults, most often experience an illness resembling a common cold, which is one reason RSV is likely underdiagnosed in this population. Because RSV symptoms overlap heavily with influenza, COVID-19, and the common cold, distinguishing between them based on symptoms alone is not reliable.
When RSV Becomes Serious
Bronchiolitis, an inflammation of the small airways in the lungs, represents one of the most common serious complications, particularly in infants under one year old. Pneumonia can develop when the infection spreads deeper into the lungs, and both bronchiolitis and pneumonia can cause significant breathing difficulty requiring medical intervention or hospitalization.
Dehydration is a genuine risk, particularly in infants who may struggle to feed normally while congested or breathing rapidly. Very young infants, especially those born prematurely, face substantially higher risk of severe disease. Older adults represent another high-risk group, along with people managing chronic heart or lung conditions and those who are immunocompromised. Public health guidance consistently identifies these groups as facing meaningfully elevated risk of severe RSV outcomes compared to the general population.
How RSV Spreads and Why It Appears Seasonally
RSV spreads primarily through respiratory droplets released when an infected person coughs or sneezes, as well as through close personal contact. Contaminated surfaces can also play a role, since the virus can survive on hard surfaces for several hours, allowing transmission when someone touches a contaminated surface and then their face.
Household and childcare settings see particularly high transmission rates given close, prolonged contact between people, especially children. RSV follows a seasonal pattern in most regions, typically circulating more heavily during fall and winter months in temperate climates, though exact timing varies by geography. Regions closer to the equator or in the Southern Hemisphere often see different seasonal timing, which is why local public health guidance should always take precedence over generalized seasonal assumptions.
How Doctors Diagnose RSV
Clinical assessment based on symptoms and physical examination often provides enough information for doctors to suspect RSV, particularly during peak season. Testing becomes more useful when results would change clinical management, such as in hospitalized patients or those at high risk for complications.
Nucleic acid amplification tests, including PCR-based testing, offer high sensitivity for confirming RSV infection and are considered a highly reliable diagnostic method. Antigen testing can provide quicker results but is generally somewhat less sensitive than PCR-based methods, meaning it can occasionally miss infections that a more sensitive test would catch. Both testing limitations mean that a negative antigen test does not always fully rule out infection in a patient with a strongly suggestive clinical picture.
RSV Treatment: What Actually Helps
Most RSV infections resolve on their own through supportive care rather than specific antiviral treatment. Ensuring adequate fluid intake helps prevent dehydration, particularly important for infants who may feed poorly while congested. Fever and discomfort can typically be managed with appropriate over-the-counter medications suited to the patient’s age, following standard dosing guidance.
Respiratory support, ranging from supplemental oxygen to more intensive interventions, becomes necessary for severe cases, typically managed in a hospital setting. Antibiotics do not treat RSV, since it is a viral infection, and should only be used if a separate bacterial infection develops as a complication.
Red Flags That Need Medical Attention
Difficulty breathing, including rapid breathing, visible chest retractions, or flaring nostrils, warrants prompt medical evaluation. Poor fluid intake or signs of dehydration, such as reduced wet diapers in infants or noticeably decreased urination in adults, should also prompt a call to a healthcare provider. Chest pain or pressure in adults deserves urgent attention, as does any rapid worsening of symptoms after initial improvement.
Significant lethargy, unusual sleepiness, or visible breathing problems in infants represent particularly urgent warning signs given how quickly young infants can decline. These situations call for prompt professional medical evaluation rather than attempting to manage symptoms based on general online guidance.
RSV Prevention Has Changed Dramatically
Prevention against severe RSV disease has advanced substantially since 2023, moving from limited options to a genuinely comprehensive set of tools spanning pregnancy, infancy, and older adulthood. Maternal RSV vaccination, given during a specific window of pregnancy, allows the mother to pass protective antibodies to her infant before birth.
Infant monoclonal antibody options provide direct, ready-made antibody protection to newborns and young infants who did not receive protection through maternal vaccination. Adult RSV vaccination is now recommended for specific older age groups and people at elevated risk.
Because these strategies differ by age group, risk profile, pregnancy status, and country-specific recommendations, guidance should always be confirmed against current national or regional public health sources rather than assumed to be universal. The World Health Organization currently identifies both maternal RSV vaccination and long-acting infant monoclonal antibodies as key tools for reducing severe infant RSV disease globally, while country-specific eligibility and scheduling should be checked against local health authority guidance, such as CDC recommendations in the United States.
The Companies Behind RSV Prevention
| Product | Company | Type | Primary Use |
|---|---|---|---|
| Abrysvo | Pfizer | Protein subunit vaccine | Adults 60+, high-risk adults 18-59, maternal immunization |
| Arexvy | GSK | Protein subunit vaccine | Adults 50+ and high-risk adults |
| mResvia | Moderna | mRNA vaccine | Adults 60+ and high-risk adults 18-59 |
| Beyfortus (nirsevimab) | Sanofi and AstraZeneca | Monoclonal antibody | Infants, first RSV season, some second season high risk children |
| Enflonsia (clesrovimab) | Merck | Monoclonal antibody | Infants, first RSV season |
Vaccines work by training the immune system to produce its own protective antibodies and generally provide longer-lasting protection measured in years, while monoclonal antibodies deliver pre-made antibodies directly into the body, offering immediate but temporary protection lasting roughly one RSV season. This distinction explains why infants typically receive a monoclonal antibody rather than a vaccine, since their immune systems respond differently to vaccination than older children and adults.
What Is Changing in RSV Prevention and Research?
Infant protection options have expanded meaningfully with the addition of a second monoclonal antibody choice, giving healthcare systems more supply flexibility during high-demand seasons. Both nirsevimab and clesrovimab now carry real-world effectiveness data beyond their original clinical trials, showing strong reductions in RSV-related hospitalization among infants.
Adult vaccines continue accumulating multi-year effectiveness data as more RSV seasons pass since their initial approval, helping clarify how durable protection actually is over time and whether booster doses may eventually be recommended. Surveillance systems tracking RSV activity have also improved, helping public health authorities time vaccination campaigns and antibody distribution more precisely each season.
Global access and affordability remain ongoing challenges, particularly for lower-income countries where the newest prevention tools are not always readily available. Because approvals, recommendations, and product availability continue evolving each RSV season, readers should verify current guidance through CDC, WHO, or relevant national health authority sources before making prevention decisions.
RSV Versus a Cold, Flu, and COVID-19
| Feature | RSV | Common Cold | Influenza | COVID-19 |
|---|---|---|---|---|
| Typical severity | Mild to severe, especially in infants and older adults | Usually mild | Mild to severe | Mild to severe |
| Key risk groups | Infants, older adults, chronic conditions | Generally low risk | Older adults, chronic conditions | Older adults, chronic conditions |
| Confirmatory testing | PCR or antigen test | Rarely tested | PCR or antigen test | PCR or antigen test |
| Specific prevention | Vaccines and monoclonal antibodies | None | Annual vaccine | Vaccines available |
Symptoms alone cannot reliably distinguish between these four illnesses, which is precisely why testing matters in situations where the result would change clinical management, such as for a hospitalized infant, an older adult with worsening symptoms, or anyone in a high-risk group.
Recognizing warning signs and following current, age-appropriate prevention guidance offers far more practical value than attempting to identify RSV from symptoms alone. Anyone with concerning symptoms, a high-risk medical history, or questions about vaccination or antibody eligibility should consult an appropriate healthcare professional for personalized guidance.
FAQ
Q: What are the first symptoms of RSV?
A: Early RSV symptoms typically include a runny nose, congestion, reduced appetite, sneezing, and a mild fever, often followed by cough as the infection progresses.
Q: How long does RSV usually last?
A: Most RSV infections resolve within one to two weeks, though cough can sometimes linger longer, and severe cases requiring hospitalization can take additional time to recover fully.
Q: Is RSV contagious?
A: Yes, RSV spreads easily through respiratory droplets from coughing or sneezing, close contact, and contaminated surfaces, making it highly contagious, particularly in households and childcare settings.
Q: How is RSV diagnosed?
A: Diagnosis often relies on clinical assessment of symptoms, with PCR or antigen testing used when results would meaningfully change treatment decisions, such as in hospitalized or high-risk patients.
Q: Is there a treatment for RSV?
A: Most RSV infections are managed through supportive care, including fluids and fever management, since routine antiviral treatment is not generally recommended for typical, uncomplicated cases.
Q: When should someone with RSV seek medical care?
A: Medical care should be sought for difficulty breathing, signs of dehydration, chest pain, rapidly worsening symptoms, or significant lethargy or breathing problems in infants.
Q: Is RSV dangerous for babies?
A: Yes, RSV can be particularly dangerous for very young infants, especially those born prematurely, since it can progress to bronchiolitis or pneumonia requiring hospitalization.
Q: Can adults get RSV?
A: Yes, adults can get RSV, and while it often resembles a common cold in healthy adults, it can cause serious illness in older adults and those with certain chronic health conditions.
Q: Is there an RSV vaccine?
A: Yes, three RSV vaccines, Abrysvo, Arexvy, and mResvia, are approved for older adults and certain high-risk younger adults, with Abrysvo also approved for use during pregnancy.
Q: What is the difference between an RSV vaccine and nirsevimab?
A: A vaccine trains the body’s own immune system to produce antibodies over time, while nirsevimab is a monoclonal antibody that delivers pre-made antibodies directly, offering immediate but temporary protection typically used for infants.
Q: Which companies make RSV vaccines?
A: Pfizer makes Abrysvo, GSK makes Arexvy, and Moderna makes mResvia, while Sanofi and AstraZeneca jointly market the monoclonal antibody Beyfortus, and Merck markets the monoclonal antibody Enflonsia.
Q: Can someone get RSV more than once?
A: Yes, RSV infection does not provide permanent immunity, so reinfection can occur, though prior infection and vaccination can reduce the severity of subsequent illness.